Fewer than one in 10 patients that would benefit from GLP-1 drugs like Wegovy can access them, warns the global health agency as it publishes its first guidance on the medications.
Given in excess of 1,000,000,000 people worldwide currently obese, it is urging more widespread and fairer availability to this class of drugs.
According to projections, more than two billion will be obese by 2030 without intervention.
"Our latest guidelines affirms that obesity is a long-term condition that can be treated with thorough and ongoing support," stated the agency's head Tedros Adhanom Ghebreyesus.
Significant expense, insufficient output, and distribution challenges are key obstacles to universal access to the treatments that can help people shift considerable body mass, explains the organization.
Skinny Jab Supply Crisis
Even in the present most optimistic outlook, the production of such drugs might only reach about 100 million people – under 10% of those who need them, according to the WHO.
The guideline urges governments and firms to widen availability, through measures like patent sharing.
Exclusive production rights on the active ingredient – the core ingredient of Novo Nordisk's Wegovy – is set to lapse in a number of nations in 2026.
How Weight-Loss Jabs Function
GLP-1 drugs imitate a biological compound to reduce digestion speed, reduce hunger and boost the sense of being full so people reduce food intake.
Patients usually see weight reduction after several weeks of beginning the regular doses.
Studies points to people may regain a significant portion within a year of stopping the medication, when their typical hunger return.
To be carrying excess weight elevates your likelihood for contracting diseases, including diabetes, cardiovascular issues, stroke, and certain malignancies.
Obesity concerns individuals in countries worldwide and was associated with millions of deaths worldwide in 2024, according to the health agency.
